- Home
- NZF vs ZLAB Comparison
NZF vs ZLAB Comparison
Compare NZF & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NZF | ZLAB |
|---|---|---|
| Founded | 2001 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.2B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | NZF | ZLAB |
|---|---|---|
| Price | $12.75 | $19.70 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $57.22 |
| AVG Volume (30 Days) | 496.8K | ★ 942.4K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 4.67% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $441,629,000.00 |
| Revenue This Year | N/A | $40.71 |
| Revenue Next Year | N/A | $50.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 24.14 |
| 52 Week Low | $9.82 | $19.40 |
| 52 Week High | $12.29 | $44.34 |
Technical Indicators
Market Signals| Indicator | NZF | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 60.87 | 23.71 |
| Support Level | $12.56 | $19.40 |
| Resistance Level | $12.73 | $20.47 |
| Average True Range (ATR) | 0.10 | 0.54 |
| MACD | 0.01 | 0.20 |
| Stochastic Oscillator | 84.00 | 9.79 |
Price Performance
Historical ComparisonAbout NZF Nuveen Municipal Credit Income Fund
Nuveen Municipal Credit Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax and to enhance portfolio value relative to the municipal bond market by investing in an actively managed portfolio of tax-exempt municipal securities.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.